These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 15728150

  • 1. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.
    Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A.
    J Antimicrob Chemother; 2005 Apr; 55(4):535-41. PubMed ID: 15728150
    [Abstract] [Full Text] [Related]

  • 2. Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome.
    Nguyen LH, Hsu DI, Ganapathy V, Shriner K, Wong-Beringer A.
    J Antimicrob Chemother; 2008 Mar; 61(3):714-20. PubMed ID: 18222951
    [Abstract] [Full Text] [Related]

  • 3. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
    Paladino JA, Sunderlin JL, Forrest A, Schentag JJ.
    J Antimicrob Chemother; 2003 Sep; 52(3):457-63. PubMed ID: 12888598
    [Abstract] [Full Text] [Related]

  • 4. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy.
    Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO.
    Clin Infect Dis; 2005 Oct 01; 41(7):923-9. PubMed ID: 16142655
    [Abstract] [Full Text] [Related]

  • 5. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.
    Yakupogullari Y, Otlu B, Dogukan M, Gursoy C, Korkmaz E, Kizirgil A, Ozden M, Durmaz R.
    Am J Infect Control; 2008 Dec 01; 36(10):e13-8. PubMed ID: 19084158
    [Abstract] [Full Text] [Related]

  • 6. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment.
    Philippe E, Weiss M, Shultz JM, Yeomans F, Ehrenkranz NJ.
    Clin Perform Qual Health Care; 1999 Dec 01; 7(2):83-7. PubMed ID: 10747571
    [Abstract] [Full Text] [Related]

  • 7. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN, Micek ST, Reichley RM, Ritchie DJ.
    Clin Ther; 2009 Feb 01; 31(2):299-310. PubMed ID: 19302902
    [Abstract] [Full Text] [Related]

  • 8. Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: risk factors and mortality.
    Furtado GH, Bergamasco MD, Menezes FG, Marques D, Silva A, Perdiz LB, Wey SB, Medeiros EA.
    J Crit Care; 2009 Dec 01; 24(4):625.e9-14. PubMed ID: 19592213
    [Abstract] [Full Text] [Related]

  • 9. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections.
    Cao B, Wang H, Sun H, Zhu Y, Chen M.
    J Hosp Infect; 2004 Jun 01; 57(2):112-8. PubMed ID: 15183240
    [Abstract] [Full Text] [Related]

  • 10. Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia.
    Scheetz MH, Bolon MK, Scarsi KK, Fotis MA, Postelnick MJ.
    J Infect; 2006 Feb 01; 52(2):105-10. PubMed ID: 15904961
    [Abstract] [Full Text] [Related]

  • 11. Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-beta-lactamase in two tertiary-care teaching hospitals.
    Zavascki AP, Barth AL, Gaspareto PB, Gonçalves AL, Moro AL, Fernandes JF, Goldani LZ.
    J Antimicrob Chemother; 2006 Oct 01; 58(4):882-5. PubMed ID: 16895936
    [Abstract] [Full Text] [Related]

  • 12. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M, Marco F, Soriano A, Almela M, Martínez JA, Muñoz A, Mensa J.
    J Antimicrob Chemother; 2009 Mar 01; 63(3):568-74. PubMed ID: 19126669
    [Abstract] [Full Text] [Related]

  • 13. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ, Liu HY, Lin YC, Sun KL, Chun CL, Hsueh PR.
    Int J Antimicrob Agents; 2010 Mar 01; 35(3):261-4. PubMed ID: 20045290
    [Abstract] [Full Text] [Related]

  • 14. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact.
    Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E.
    Am J Med; 2006 Jun 01; 119(6):526.e19-25. PubMed ID: 16750968
    [Abstract] [Full Text] [Related]

  • 15. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.
    Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW.
    Clin Infect Dis; 2003 Sep 15; 37(6):745-51. PubMed ID: 12955633
    [Abstract] [Full Text] [Related]

  • 16. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients.
    Zavascki AP, Cruz RP, Goldani LZ.
    J Hosp Infect; 2005 Feb 15; 59(2):96-101. PubMed ID: 15620442
    [Abstract] [Full Text] [Related]

  • 17. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes.
    Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG, Heyland DK, Canadian Critical Care Trials Group.
    J Crit Care; 2008 Mar 15; 23(1):18-26. PubMed ID: 18359417
    [Abstract] [Full Text] [Related]

  • 18. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.
    Obritsch MD, Fish DN, MacLaren R, Jung R.
    Pharmacotherapy; 2005 Oct 15; 25(10):1353-64. PubMed ID: 16185180
    [Abstract] [Full Text] [Related]

  • 19. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.
    Lodise TP, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC.
    Antimicrob Agents Chemother; 2007 Oct 15; 51(10):3510-5. PubMed ID: 17646415
    [Abstract] [Full Text] [Related]

  • 20. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit.
    Ozkurt Z, Ertek M, Erol S, Altoparlak U, Akcay MN.
    Burns; 2005 Nov 15; 31(7):870-3. PubMed ID: 15975720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.